AgomAb Therapeutics NV’s Lock-Up Period Will Expire Tomorrow (NASDAQ:AGMB)

AgomAb Therapeutics’ (NASDAQ:AGMB) lock-up period is set to expire on Wednesday, August 5th. AgomAb Therapeutics had issued 12,500,000 shares in its initial public offering on February 6th. The total size of the offering was $200,000,000 based on an initial share price of $16.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on AGMB shares. B. Riley Financial initiated coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. HC Wainwright started coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $33.00.

AgomAb Therapeutics Price Performance

Shares of NASDAQ:AGMB opened at $13.52 on Tuesday. The company’s fifty day moving average is $12.01. AgomAb Therapeutics has a 12-month low of $8.75 and a 12-month high of $17.82.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.